Caremark Issues Statement on Questcor's (QCOR) Acthar Gel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Boeing nears approval of 737 MAX anti-ice fix, paving way for deliveries
Questcor (QCOR) Updates on Study of Acthar for MS Patients When Regular Treatment Doesn't
March 11, 2013 11:42 AM EDTQuestcor (Nasdaq: QCOR) shares are on the rise following more positive data tied to its ACTH treatment, Acthar.
According to Bloomberg, the American Academy Neurology released data from a new study outlining the benefits of Acthar on multiple sclerosis (MS) which isn't being well controlled via regular treatment. The release, posted on Science Daily is reprinted below:
A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released... More
Questcor (QCOR) Updates on Study of Acthar for MS Patients When Regular Treatment Doesn't
March 11, 2013 11:42 AM EDTQuestcor (Nasdaq: QCOR) shares are on the rise following more positive data tied to its ACTH treatment, Acthar.
According to Bloomberg, the American Academy Neurology released data from a new study outlining the benefits of Acthar on multiple sclerosis (MS) which isn't being well controlled via regular treatment. The release, posted on Science Daily is reprinted below:
A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released... More
